{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T01:01:56Z","timestamp":1793235716971,"version":"4.5.0"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T00:00:00Z","timestamp":1726012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T00:00:00Z","timestamp":1726012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s13346-024-01700-z","type":"journal-article","created":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T14:03:20Z","timestamp":1726063400000},"page":"1626-1645","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["In Vitro and in vivo characterization of nasal pH-Responsive in-situ hydrogel of Candesartan-loaded invasomes as a potential stroke treatment"],"prefix":"10.1007","volume":"15","author":[{"given":"Shaimaa","family":"El-Housiny","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0082-4160","authenticated-orcid":false,"given":"Amr Gamal","family":"Fouad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana","family":"El-Bakry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randa Mohammed","family":"Zaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Obaid","family":"Afzal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatma I. Abo","family":"El-Ela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maha M.","family":"Ghalwash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,11]]},"reference":[{"issue":"1","key":"1700_CR1","doi-asserted-by":"publisher","first-page":"26","DOI":"10.5853\/jos.2022.02306","volume":"25","author":"O Mosenzon","year":"2023","unstructured":"Mosenzon O, et al. Diabetes and stroke: what are the connections? J Stroke. 2023;25(1):26\u201338.","journal-title":"J Stroke"},{"issue":"5","key":"1700_CR2","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.jdiacomp.2014.12.008","volume":"29","author":"L Policardo","year":"2015","unstructured":"Policardo L, et al. Gender difference in diabetes-associated risk of first-ever and recurrent ischemic stroke. J Diabetes Complicat. 2015;29(5):713\u20137.","journal-title":"J Diabetes Complicat"},{"issue":"05","key":"1700_CR3","doi-asserted-by":"publisher","first-page":"544","DOI":"10.4172\/2155-6156.1000544","volume":"6","author":"A Tuttolomondo","year":"2015","unstructured":"Tuttolomondo A, et al. Relationship between diabetes and ischemic stroke: analysis of diabetes-related risk factors for stroke and of specific patterns of stroke associated with diabetes mellitus. J Diabetes Metab. 2015;6(05):544\u201351.","journal-title":"J Diabetes Metab"},{"issue":"3","key":"1700_CR4","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1161\/CIRCRESAHA.116.308413","volume":"120","author":"VL Feigin","year":"2017","unstructured":"Feigin VL, Norrving B, Mensah GA. Global burden of stroke. Circul Res. 2017;120(3):439\u201348.","journal-title":"Circul Res"},{"issue":"2","key":"1700_CR5","doi-asserted-by":"publisher","first-page":"111","DOI":"10.15420\/ecr.2019.11.1","volume":"14","author":"M Wajngarten","year":"2019","unstructured":"Wajngarten M, Silva GS. Hypertension and stroke: update on treatment. Eur Cardiol Rev. 2019;14(2):111.","journal-title":"Eur Cardiol Rev"},{"issue":"9735","key":"1700_CR6","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/S0140-6736(10)60834-3","volume":"376","author":"D Xavier","year":"2010","unstructured":"Xavier D, et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet. 2010;376(9735):112\u201323.","journal-title":"Lancet"},{"issue":"5","key":"1700_CR7","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1161\/STROKEAHA.111.000302","volume":"44","author":"Y Wang","year":"2013","unstructured":"Wang Y, et al. Association of hypertension with stroke recurrence depends on ischemic stroke subtype. Stroke. 2013;44(5):1232\u20137.","journal-title":"Stroke"},{"key":"1700_CR8","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2165\/00129784-200707010-00003","volume":"7","author":"J Schrader","year":"2007","unstructured":"Schrader J, Kulschewski A, Dendorfer A. Inhibition of the renin-angiotensin system and the prevention of stroke. Am J Cardiovasc Drugs. 2007;7:25\u201337.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"7","key":"1700_CR9","doi-asserted-by":"publisher","first-page":"3876","DOI":"10.3390\/ijms23073876","volume":"23","author":"S Andone","year":"2022","unstructured":"Andone S, et al. Neuroprotection in Stroke\u2014Focus on the renin-angiotensin system: a systematic review. Int J Mol Sci. 2022;23(7):3876.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"1700_CR10","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1159\/000525672","volume":"56","author":"Y Yin","year":"2022","unstructured":"Yin Y, et al. Statin therapy for preventing recurrent stroke in patients with ischemic stroke: a systematic review and meta-analysis of randomized controlled trials and observational cohort studies. Neuroepidemiology. 2022;56(4):240\u20139.","journal-title":"Neuroepidemiology"},{"issue":"13","key":"1700_CR11","doi-asserted-by":"publisher","first-page":"6738","DOI":"10.3390\/ijms22136738","volume":"22","author":"C Delaitre","year":"2021","unstructured":"Delaitre C, et al. Targeting the angiotensin II type 1 receptor in cerebrovascular diseases: biased signaling raises new hopes. Int J Mol Sci. 2021;22(13):6738.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"1700_CR12","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1161\/HYPERTENSIONAHA.120.16667","volume":"78","author":"R Chen","year":"2021","unstructured":"Chen R, et al. Comparative first-line effectiveness and safety of ACE (angiotensin-converting enzyme) inhibitors and angiotensin receptor blockers: a multinational cohort study. Hypertension. 2021;78(3):591\u2013603.","journal-title":"Hypertension"},{"issue":"1","key":"1700_CR13","doi-asserted-by":"publisher","first-page":"2179127","DOI":"10.1080\/10717544.2023.2179127","volume":"30","author":"SA Sabry","year":"2023","unstructured":"Sabry SA, et al. Brain-targeted delivery of Valsartan using solid lipid nanoparticles labeled with rhodamine B; a promising technique for mitigating the negative effects of stroke. Drug Delivery. 2023;30(1):2179127.","journal-title":"Drug Delivery"},{"issue":"2","key":"1700_CR14","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1007\/s12975-023-01125-9","volume":"15","author":"RG Thomas","year":"2024","unstructured":"Thomas RG, et al. Treatment of ischemic stroke by atorvastatin-loaded PEGylated liposome. Translational Stroke Res. 2024;15(2):388\u201398.","journal-title":"Translational Stroke Res"},{"key":"1700_CR15","doi-asserted-by":"crossref","unstructured":"Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ, 2009. 338.","DOI":"10.1136\/bmj.b1665"},{"key":"1700_CR16","first-page":"103","volume-title":"Renin Angiotensin Aldosterone System, Glucose Homeostasis, and Prevention of Type 2 Diabetes: Mechanistic Insights and Evidence from Major Clinical Trials","author":"S Skwiersky","year":"2021","unstructured":"Skwiersky S, et al. Renin Angiotensin Aldosterone System, glucose homeostasis, and Prevention of type 2 diabetes: mechanistic insights and evidence from major clinical trials. Renin-Angiotensin Aldosterone System; 2021. p. 103."},{"issue":"3","key":"1700_CR17","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.tem.2005.02.003","volume":"16","author":"G Giacchetti","year":"2005","unstructured":"Giacchetti G, et al. The renin\u2013angiotensin\u2013aldosterone system, glucose metabolism and diabetes. Trends Endocrinol Metabolism. 2005;16(3):120\u20136.","journal-title":"Trends Endocrinol Metabolism"},{"issue":"14","key":"1700_CR18","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1161\/01.CIR.0000143627.55926.4C","volume":"110","author":"MT Johnstone","year":"2004","unstructured":"Johnstone MT, et al. Angiotensin receptor blockade with candesartan attenuates atherosclerosis, plaque disruption, and macrophage accumulation within the plaque in a rabbit model. Circulation. 2004;110(14):2060\u20135.","journal-title":"Circulation"},{"key":"1700_CR19","first-page":"p12","volume":"Issue","author":"A Husain","year":"2011","unstructured":"Husain A, et al. A review on candesartan: pharmacological and pharmaceutical profile. J Appl Pharm Sci. 2011;Issue:p12\u201317.","journal-title":"J Appl Pharm Sci"},{"issue":"1","key":"1700_CR20","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1007\/s12011-022-03153-2","volume":"201","author":"S Balarastaghi","year":"2023","unstructured":"Balarastaghi S, et al. Mechanisms of arsenic exposure-induced hypertension and atherosclerosis: an updated overview. Biol Trace Elem Res. 2023;201(1):98\u2013113.","journal-title":"Biol Trace Elem Res"},{"key":"1700_CR21","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/2356507","volume-title":"Candesartan Reduces Neuronal Apoptosis Caused by Ischemic Stroke via Regulating the FFAR1\/ITGA4 Pathway","author":"Y Ding","year":"2022","unstructured":"Ding Y, et al. Candesartan reduces neuronal apoptosis caused by ischemic stroke via regulating the FFAR1\/ITGA4 pathway. Mediators of Inflammation; 2022."},{"key":"1700_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12933-019-0891-4","volume":"18","author":"S H\u00e4gg-Holmberg","year":"2019","unstructured":"H\u00e4gg-Holmberg S, et al. The role of blood pressure in risk of ischemic and hemorrhagic stroke in type 1 diabetes. Cardiovasc Diabetol. 2019;18:1\u20139.","journal-title":"Cardiovasc Diabetol"},{"issue":"5","key":"1700_CR23","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1161\/STROKEAHA.108.537225","volume":"40","author":"A Kozak","year":"2009","unstructured":"Kozak A, et al. Candesartan augments ischemia-induced proangiogenic state and results in sustained improvement after stroke. Stroke. 2009;40(5):1870\u20136.","journal-title":"Stroke"},{"issue":"10","key":"1700_CR24","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1161\/01.STR.31.10.2478","volume":"31","author":"Y Nishimura","year":"2000","unstructured":"Nishimura Y, Ito T, Saavedra JM. Angiotensin II AT1 blockade normalizes cerebrovascular autoregulation and reduces cerebral ischemia in spontaneously hypertensive rats. Stroke. 2000;31(10):2478\u201386.","journal-title":"Stroke"},{"issue":"5","key":"1700_CR25","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1161\/01.STR.0000217404.64352.d7","volume":"37","author":"J Zhou","year":"2006","unstructured":"Zhou J, et al. AT1 receptor blockade regulates the local angiotensin II system in cerebral microvessels from spontaneously hypertensive rats. Stroke. 2006;37(5):1271\u20136.","journal-title":"Stroke"},{"issue":"2","key":"1700_CR26","doi-asserted-by":"publisher","first-page":"395","DOI":"10.3109\/10717544.2014.914986","volume":"23","author":"N Dudhipala","year":"2016","unstructured":"Dudhipala N, Veerabrahma K. Candesartan cilexetil loaded solid lipid nanoparticles for oral delivery: characterization, pharmacokinetic and pharmacodynamic evaluation. Drug Delivery. 2016;23(2):395\u2013404.","journal-title":"Drug Delivery"},{"issue":"5","key":"1700_CR27","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.nano.2011.08.016","volume":"8","author":"Z Zhang","year":"2012","unstructured":"Zhang Z, et al. Solid lipid nanoparticles loading candesartan cilexetil enhance oral bioavailability: in vitro characteristics and absorption mechanism in rats. Nanomed Nanotechnol Biol Med. 2012;8(5):740\u20137.","journal-title":"Nanomed Nanotechnol Biol Med"},{"key":"1700_CR28","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.2147\/DDDT.S248511","volume":"14","author":"UF Aly","year":"2020","unstructured":"Aly UF, et al. Applying different techniques to improve the bioavailability of candesartan cilexetil antihypertensive drug. Drug Des Devel Ther. 2020;14:1851\u201365.","journal-title":"Drug Des Devel Ther"},{"issue":"9","key":"1700_CR29","doi-asserted-by":"publisher","first-page":"659","DOI":"10.3390\/membranes11090659","volume":"11","author":"OY Mady","year":"2021","unstructured":"Mady OY, et al. Formulation and bioavailability of novel mucoadhesive buccal films for candesartan cilexetil in rats. Membranes. 2021;11(9):659.","journal-title":"Membranes"},{"issue":"11","key":"1700_CR30","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.3390\/pharmaceutics12111047","volume":"12","author":"W Anwar","year":"2020","unstructured":"Anwar W, et al. Enhancing the oral bioavailability of candesartan cilexetil loaded nanostructured lipid carriers: in vitro characterization and absorption in rats after oral administration. Pharmaceutics. 2020;12(11):1047.","journal-title":"Pharmaceutics"},{"key":"1700_CR31","doi-asserted-by":"crossref","unstructured":"Aly UF, et al. Applying different techniques to improve the bioavailability of candesartan cilexetil antihypertensive drug. Drug Design, Development and Therapy; 2020. pp. 1851\u201365.","DOI":"10.2147\/DDDT.S248511"},{"key":"1700_CR32","doi-asserted-by":"crossref","unstructured":"Singh AK, Singh A, Madhv NS. Nasal cavity, a promising transmucosal platform for drug delivery and research approaches from nasal to brain targetting. J drug Delivery Ther, 2012. 2(3).","DOI":"10.22270\/jddt.v2i3.163"},{"key":"1700_CR33","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.reactfunctpolym.2016.01.011","volume":"100","author":"S Mansuri","year":"2016","unstructured":"Mansuri S, et al. Mucoadhesion: a promising approach in drug delivery system. Reactive Funct Polym. 2016;100:151\u201372.","journal-title":"Reactive Funct Polym"},{"key":"1700_CR34","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.ijbiomac.2019.02.005","volume":"129","author":"V Piazzini","year":"2019","unstructured":"Piazzini V, et al. Chitosan coated human serum albumin nanoparticles: a promising strategy for nose-to-brain drug delivery. Int J Biol Macromol. 2019;129:267\u201380.","journal-title":"Int J Biol Macromol"},{"key":"1700_CR35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s43094-020-00150-x","volume":"7","author":"GA Girnar","year":"2021","unstructured":"Girnar GA, Mahajan HS. Cerebral ischemic stroke and different approaches for treatment of stroke. Future J Pharm Sci. 2021;7:1\u201310.","journal-title":"Future J Pharm Sci"},{"issue":"1","key":"1700_CR36","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1080\/10717544.2022.2064564","volume":"29","author":"X Li","year":"2022","unstructured":"Li X, et al. Preparation of baicalin-loaded ligand-modified nanoparticles for nose-to-brain delivery for neuroprotection in cerebral ischemia. Drug Delivery. 2022;29(1):1282\u201398.","journal-title":"Drug Delivery"},{"issue":"10","key":"1700_CR37","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1016\/j.ymthe.2018.08.024","volume":"26","author":"C Alzheimer","year":"2018","unstructured":"Alzheimer C. Nasal spray to the rescue of neurons in stroke. Mol Ther. 2018;26(10):2333\u20134.","journal-title":"Mol Ther"},{"issue":"11","key":"1700_CR38","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.3390\/biom11111587","volume":"11","author":"SK Zaidi","year":"2021","unstructured":"Zaidi SK, et al. Nebulization of low-dose S-Nitrosoglutathione in Diabetic Stroke enhances benefits of reperfusion and prevents Post-thrombolysis Hemorrhage. Biomolecules. 2021;11(11):1587.","journal-title":"Biomolecules"},{"key":"1700_CR39","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.jconrel.2014.05.003","volume":"190","author":"L Casettari","year":"2014","unstructured":"Casettari L, Illum L. Chitosan in nasal delivery systems for therapeutic drugs. J Controlled Release. 2014;190:189\u2013200.","journal-title":"J Controlled Release"},{"issue":"3","key":"1700_CR40","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.yrtph.2009.09.015","volume":"56","author":"P Baldrick","year":"2010","unstructured":"Baldrick P. The safety of Chitosan as a pharmaceutical excipient. Regul Toxicol Pharmacol. 2010;56(3):290\u20139.","journal-title":"Regul Toxicol Pharmacol"},{"key":"1700_CR41","first-page":"100316","volume":"5","author":"G Kaur","year":"2023","unstructured":"Kaur G, et al. Unraveling the role of chitosan for nasal drug delivery systems: a review. Carbohydr Polym Technol Appl. 2023;5:100316.","journal-title":"Carbohydr Polym Technol Appl"},{"issue":"2","key":"1700_CR42","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2174\/2212697X06666190102105652","volume":"5","author":"SK Kushwaha","year":"2018","unstructured":"Kushwaha SK, Kumar P, Rai AK. Formulation and evaluation of pH Sensitive Sustained Release Hydrogel of Methotrexate. Clin Cancer Drugs. 2018;5(2):105\u201312.","journal-title":"Clin Cancer Drugs"},{"issue":"2","key":"1700_CR43","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1080\/08982104.2019.1601213","volume":"30","author":"HF Salem","year":"2020","unstructured":"Salem HF, et al. Treatment of breast cancer with engineered novel pH-sensitive triaryl-(Z)-olefin niosomes containing hydrogel: an in vitro and in vivo study. J Liposome Res. 2020;30(2):126\u201335.","journal-title":"J Liposome Res"},{"key":"1700_CR44","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s40005-014-0124-5","volume":"44","author":"SKS Kushwaha","year":"2014","unstructured":"Kushwaha SKS, Rai AK, Singh S. Formulation and evaluation of pH sensitive hydrogel of camptothecin with enhanced solubility by using \u03b2-cyclodextrin. J Pharm Invest. 2014;44:265\u201372.","journal-title":"J Pharm Invest"},{"key":"1700_CR45","doi-asserted-by":"publisher","first-page":"102166","DOI":"10.1016\/j.jddst.2020.102166","volume":"61","author":"S Jain","year":"2021","unstructured":"Jain S, Tripathi S, Tripathi PK. Invasomes: potential vesicular systems for transdermal delivery of drug molecules. J Drug Deliv Sci Technol. 2021;61:102166.","journal-title":"J Drug Deliv Sci Technol"},{"issue":"1","key":"1700_CR46","doi-asserted-by":"publisher","first-page":"26","DOI":"10.4103\/0975-8453.135837","volume":"4","author":"P Lakshmi","year":"2013","unstructured":"Lakshmi P, Kalpana B, Prasanthi D. Invasomes-novel vesicular carriers for enhanced skin permeation. Syst Reviews Pharm. 2013;4(1):26.","journal-title":"Syst Reviews Pharm"},{"issue":"2","key":"1700_CR47","doi-asserted-by":"publisher","first-page":"126","DOI":"10.3390\/ph15020126","volume":"15","author":"HF Salem","year":"2022","unstructured":"Salem HF, et al. Enhancing the bioavailability and efficacy of Vismodegib for the control of skin cancer: in vitro and in vivo studies. Pharmaceuticals. 2022;15(2):126.","journal-title":"Pharmaceuticals"},{"key":"1700_CR48","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.2147\/IJN.S105016","volume":"11","author":"IM Abdulbaqi","year":"2016","unstructured":"Abdulbaqi IM, et al. Ethosomal nanocarriers: the impact of constituents and formulation techniques on ethosomal properties, in vivo studies, and clinical trials. Int J Nanomed. 2016;11:2279.","journal-title":"Int J Nanomed"},{"key":"1700_CR49","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s12272-012-0112-0","volume":"35","author":"J-P Zhang","year":"2012","unstructured":"Zhang J-P, et al. Ethosomes, binary ethosomes and transfersomes of terbinafine hydrochloride: a comparative study. Arch Pharm Res. 2012;35:109\u201317.","journal-title":"Arch Pharm Res"},{"issue":"3","key":"1700_CR50","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/S0168-3659(99)00222-9","volume":"65","author":"E Touitou","year":"2000","unstructured":"Touitou E, et al. Ethosomes\u2014novel vesicular carriers for enhanced delivery: characterization and skin penetration properties. J Controlled Release. 2000;65(3):403\u201318.","journal-title":"J Controlled Release"},{"issue":"1","key":"1700_CR51","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1080\/10717544.2022.2072412","volume":"29","author":"ZA Awan","year":"2022","unstructured":"Awan ZA, et al. Optimized 2-methoxyestradiol invasomes fortified with apamin: a promising approach for suppression of A549 lung cancer cells. Drug Delivery. 2022;29(1):1536\u201348.","journal-title":"Drug Delivery"},{"key":"1700_CR52","doi-asserted-by":"publisher","first-page":"101556","DOI":"10.1016\/j.jddst.2020.101556","volume":"56","author":"FA Gamal","year":"2020","unstructured":"Gamal FA, et al. Control of basal cell carcinoma via positively charged ethosomes of Vismodegib: in vitro and in vivo studies. J Drug Deliv Sci Technol. 2020;56:101556.","journal-title":"J Drug Deliv Sci Technol"},{"issue":"11","key":"1700_CR53","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.3390\/ph15111306","volume":"15","author":"FIA El-Ela","year":"2022","unstructured":"El-Ela FIA, et al. In Vitro and in vivo evaluation of the effectiveness and safety of Amygdalin as a Cancer Therapy. Pharmaceuticals. 2022;15(11):1306.","journal-title":"Pharmaceuticals"},{"issue":"10","key":"1700_CR54","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.3390\/pharmaceutics13101633","volume":"13","author":"HF Salem","year":"2021","unstructured":"Salem HF, et al. The impact of improving dermal permeation on the efficacy and targeting of liposome nanoparticles as a potential treatment for breast cancer. Pharmaceutics. 2021;13(10):1633.","journal-title":"Pharmaceutics"},{"key":"1700_CR55","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/s13346-018-0499-3","volume":"8","author":"HF Salem","year":"2018","unstructured":"Salem HF, et al. Evaluation and optimization of pH-responsive niosomes as a carrier for efficient treatment of breast cancer. Drug Delivery Translational Res. 2018;8:633\u201344.","journal-title":"Drug Delivery Translational Res"},{"key":"1700_CR56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1208\/s12249-020-1626-2","volume":"21","author":"OM Sayed","year":"2020","unstructured":"Sayed OM, et al. Treatment of basal cell carcinoma via binary ethosomes of vismodegib: in vitro and in vivo studies. AAPS PharmSciTech. 2020;21:1\u201311.","journal-title":"AAPS PharmSciTech"},{"issue":"10","key":"1700_CR57","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.3390\/pharmaceutics13101560","volume":"13","author":"A Gamal","year":"2021","unstructured":"Gamal A, et al. Improving the antitumor activity and bioavailability of sonidegib for the treatment of skin cancer. Pharmaceutics. 2021;13(10):1560.","journal-title":"Pharmaceutics"},{"key":"1700_CR58","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.biopha.2018.03.107","volume":"102","author":"N Lian","year":"2018","unstructured":"Lian N, et al. Ginkgetin ameliorates experimental atherosclerosis in rats. Biomed Pharmacother. 2018;102:510\u20136.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"1700_CR59","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1080\/1028415X.2020.1724453","volume":"25","author":"P P\u00e9rez-Corredor","year":"2022","unstructured":"P\u00e9rez-Corredor P, et al. High fructose diet-induced obesity worsens post-ischemic brain injury in the hippocampus of female rats. Nutr Neurosci. 2022;25(1):122\u201336.","journal-title":"Nutr Neurosci"},{"issue":"3","key":"1700_CR60","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/S2221-1691(14)60231-8","volume":"4","author":"RC Ekeanyanwu","year":"2014","unstructured":"Ekeanyanwu RC, Njoku OU. Acute and subacute oral toxicity study on the flavonoid rich fraction of Monodora tenuifolia seed in albino rats. Asian Pac J Trop Biomed. 2014;4(3):194\u2013202.","journal-title":"Asian Pac J Trop Biomed"},{"issue":"2","key":"1700_CR61","first-page":"161","volume":"9","author":"R Kumar","year":"2017","unstructured":"Kumar R, Salwe KJ, Kumarappan M. Evaluation of antioxidant, hypolipidemic, and antiatherogenic property of lycopene and astaxanthin in atherosclerosis-induced rats. Pharmacognosy Res. 2017;9(2):161.","journal-title":"Pharmacognosy Res"},{"key":"1700_CR62","doi-asserted-by":"publisher","first-page":"107494","DOI":"10.1016\/j.intimp.2021.107494","volume":"94","author":"M Ashafaq","year":"2021","unstructured":"Ashafaq M, et al. Nanoparticles of resveratrol attenuates oxidative stress and inflammation after ischemic stroke in rats. Int Immunopharmacol. 2021;94:107494.","journal-title":"Int Immunopharmacol"},{"issue":"4","key":"1700_CR63","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/rej.2019.2230","volume":"23","author":"Y Zhao","year":"2020","unstructured":"Zhao Y, et al. Improved neuroprotective effects of gallic acid-loaded chitosan nanoparticles against ischemic stroke. Rejuven Res. 2020;23(4):284\u201392.","journal-title":"Rejuven Res"},{"key":"1700_CR64","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s10072-012-1163-1","volume":"34","author":"R Tabassum","year":"2013","unstructured":"Tabassum R, et al. Centella asiatica attenuates the neurobehavioral, neurochemical and histological changes in transient focal middle cerebral artery occlusion rats. Neurol Sci. 2013;34:925\u201333.","journal-title":"Neurol Sci"},{"issue":"6","key":"1700_CR65","doi-asserted-by":"publisher","first-page":"482","DOI":"10.3390\/life11060482","volume":"11","author":"S Bernardo-Castro","year":"2021","unstructured":"Bernardo-Castro S, et al. Therapeutic nanoparticles for the different phases of ischemic stroke. Life. 2021;11(6):482.","journal-title":"Life"},{"key":"1700_CR66","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.brainresbull.2019.07.015","volume":"152","author":"GE Bruch","year":"2019","unstructured":"Bruch GE, et al. Liposomes for drug delivery in stroke. Brain Res Bull. 2019;152:246\u201356.","journal-title":"Brain Res Bull"},{"key":"1700_CR67","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.2147\/IJN.S107292","volume":"11","author":"M Campos-Martorell","year":"2016","unstructured":"Campos-Martorell M, et al. Charge effect of a liposomal delivery system encapsulating simvastatin to treat experimental ischemic stroke in rats. Int J Nanomed. 2016;11:3035\u201348.","journal-title":"Int J Nanomed"},{"issue":"5","key":"1700_CR68","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1096\/fj.201601209R","volume":"31","author":"T Fukuta","year":"2017","unstructured":"Fukuta T, et al. Combination therapy with liposomal neuroprotectants and tissue plasminogen activator for treatment of ischemic stroke. FASEB J. 2017;31(5):1879\u201390.","journal-title":"FASEB J"},{"issue":"3","key":"1700_CR69","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1166\/jbn.2008.320","volume":"4","author":"RR Patil","year":"2008","unstructured":"Patil RR, et al. Role of lipids in enhancing splenic uptake of polymer-lipid (LIPOMER) nanoparticles. J Biomed Nanotechnol. 2008;4(3):359\u201366.","journal-title":"J Biomed Nanotechnol"},{"key":"1700_CR70","doi-asserted-by":"publisher","first-page":"8893","DOI":"10.2147\/IJN.S283911","volume":"15","author":"MA Tawfik","year":"2020","unstructured":"Tawfik MA, et al. Low-frequency versus high-frequency ultrasound-mediated transdermal delivery of agomelatine-loaded invasomes: development, optimization and in-vivo pharmacokinetic assessment. Int J Nanomed. 2020;15:8893\u2013910.","journal-title":"Int J Nanomed"},{"key":"1700_CR71","doi-asserted-by":"publisher","first-page":"105686","DOI":"10.1016\/j.jddst.2024.105686","volume":"96","author":"HA Abou-Taleb","year":"2024","unstructured":"Abou-Taleb HA, et al. In vitro and in vivo evaluation of isoxsuprine loaded invasomes for efficient treatment of diabetes-accelerated atherosclerosis. J Drug Deliv Sci Technol. 2024;96:105686.","journal-title":"J Drug Deliv Sci Technol"},{"issue":"3","key":"1700_CR72","doi-asserted-by":"publisher","first-page":"733","DOI":"10.3390\/microorganisms11030733","volume":"11","author":"A Gamal","year":"2023","unstructured":"Gamal A, et al. Synthesis of Carvacrol-Loaded invasomes nanoparticles Improved Acaricide Efficacy, Cuticle Invasion and Inhibition of Acetylcholinestrase against Hard ticks. Microorganisms. 2023;11(3):733.","journal-title":"Microorganisms"},{"key":"1700_CR73","doi-asserted-by":"crossref","unstructured":"Tawfik MA et al. Low-frequency versus high-frequency ultrasound-mediated transdermal delivery of agomelatine-loaded invasomes: development, optimization and in-vivo pharmacokinetic assessment. Int J Nanomed, 2020: p. 8893\u2013910.","DOI":"10.2147\/IJN.S283911"},{"key":"1700_CR74","doi-asserted-by":"publisher","first-page":"118657","DOI":"10.1016\/j.ijpharm.2019.118657","volume":"570","author":"OA Ahmed","year":"2019","unstructured":"Ahmed OA, Badr-Eldin SM. Development of an optimized avanafil-loaded invasomal transdermal film: ex vivo skin permeation and in vivo evaluation. Int J Pharm. 2019;570:118657.","journal-title":"Int J Pharm"},{"key":"1700_CR75","doi-asserted-by":"publisher","first-page":"121080","DOI":"10.1016\/j.ijpharm.2021.121080","volume":"608","author":"FSe El-Tokhy","year":"2021","unstructured":"El-Tokhy FSe, et al. Design of long acting invasomal nanovesicles for improved transdermal permeation and bioavailability of asenapine maleate for the chronic treatment of schizophrenia. Int J Pharm. 2021;608:121080.","journal-title":"Int J Pharm"},{"issue":"1\u20132","key":"1700_CR76","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.ijpharm.2016.03.030","volume":"505","author":"M Kamran","year":"2016","unstructured":"Kamran M, et al. Design, formulation and optimization of novel soft nano-carriers for transdermal olmesartan medoxomil delivery: in vitro characterization and in vivo pharmacokinetic assessment. Int J Pharm. 2016;505(1\u20132):147\u201358.","journal-title":"Int J Pharm"},{"issue":"1","key":"1700_CR77","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s43094-022-00440-6","volume":"8","author":"B Kumar","year":"2022","unstructured":"Kumar B, et al. A comprehensive review on invasomal carriers incorporating natural terpenes for augmented transdermal delivery. Future J Pharm Sci. 2022;8(1):50.","journal-title":"Future J Pharm Sci"},{"issue":"2","key":"1700_CR78","doi-asserted-by":"publisher","first-page":"341","DOI":"10.3390\/nano10020341","volume":"10","author":"S Babaie","year":"2020","unstructured":"Babaie S, et al. Invasome: a novel nanocarrier for transdermal drug delivery. Nanomaterials. 2020;10(2):341.","journal-title":"Nanomaterials"},{"issue":"1","key":"1700_CR79","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jconrel.2007.12.013","volume":"127","author":"N Dragicevic-Curic","year":"2008","unstructured":"Dragicevic-Curic N, et al. Temoporfin-loaded invasomes: development, characterization and in vitro skin penetration studies. J Controlled Release. 2008;127(1):59\u201369.","journal-title":"J Controlled Release"},{"issue":"3","key":"1700_CR80","doi-asserted-by":"publisher","first-page":"050","DOI":"10.7324\/JAPS.2019.90308","volume":"9","author":"K Vidya","year":"2019","unstructured":"Vidya K, Lakshmi P. Cytotoxic effect of transdermal invasomal anastrozole gel on MCF-7 breast cancer cell line. J Appl Pharm Sci. 2019;9(3):050\u20138.","journal-title":"J Appl Pharm Sci"},{"issue":"1\u20132","key":"1700_CR81","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ijpharm.2004.02.014","volume":"276","author":"S Ganguly","year":"2004","unstructured":"Ganguly S, Dash AK. A novel in situ gel for sustained drug delivery and targeting. Int J Pharm. 2004;276(1\u20132):83\u201392.","journal-title":"Int J Pharm"},{"issue":"11","key":"1700_CR82","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1111\/j.1745-7254.2005.00174.x","volume":"26","author":"Yj Zhang","year":"2005","unstructured":"Zhang Yj, et al. Permeation-enhancing effects of chitosan formulations on recombinant hirudin\u20102 by nasal delivery in vitro and in vivo. Acta Pharmacol Sin. 2005;26(11):1402\u20138.","journal-title":"Acta Pharmacol Sin"},{"key":"1700_CR83","doi-asserted-by":"publisher","first-page":"102471","DOI":"10.1016\/j.jddst.2021.102471","volume":"63","author":"A Zafar","year":"2021","unstructured":"Zafar A, et al. Chitosan-ethyl cellulose microspheres of domperidone for nasal delivery: Preparation, in-vitro characterization, in-vivo study for pharmacokinetic evaluation and bioavailability enhancement. J Drug Deliv Sci Technol. 2021;63:102471.","journal-title":"J Drug Deliv Sci Technol"},{"issue":"3","key":"1700_CR84","doi-asserted-by":"publisher","first-page":"588","DOI":"10.3390\/pharmaceutics14030588","volume":"14","author":"PC Pires","year":"2022","unstructured":"Pires PC, et al. Strategies to improve drug strength in nasal preparations for brain delivery of low aqueous solubility drugs. Pharmaceutics. 2022;14(3):588.","journal-title":"Pharmaceutics"},{"issue":"21","key":"1700_CR85","doi-asserted-by":"publisher","first-page":"7064","DOI":"10.1021\/ma9908999","volume":"32","author":"B Jeong","year":"1999","unstructured":"Jeong B, Bae YH, Kim SW. Thermoreversible gelation of PEG\u2009\u2013\u2009PLGA\u2009\u2013\u2009PEG triblock copolymer aqueous solutions. Macromolecules. 1999;32(21):7064\u20139.","journal-title":"Macromolecules"},{"issue":"01","key":"1700_CR86","first-page":"15","volume":"1","author":"A Mehrabifar","year":"2017","unstructured":"Mehrabifar A, Rahmati M. Investigation of Anticancer effects of Dacarbazine Hydrogel in the Injectable form and its release. MedBioTech J. 2017;1(01):15\u201321.","journal-title":"MedBioTech J"},{"issue":"6","key":"1700_CR87","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.5958\/0974-360X.2019.00440.2","volume":"12","author":"D Elsegaie","year":"2019","unstructured":"Elsegaie D, et al. Formulation and in-vitro characterization of Self Nano-emulsifying drug delivery system (SNEDDS) for enhanced solubility of candesartan cilexetil. Res J Pharm Technol. 2019;12(6):2628\u201336.","journal-title":"Res J Pharm Technol"},{"issue":"2","key":"1700_CR88","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1007\/s13346-023-01412-w","volume":"14","author":"AG Fouad","year":"2024","unstructured":"Fouad AG, et al. Design, optimization, and in vivo evaluation of invasome-mediated candesartan for the control of diabetes-associated atherosclerosis. Drug Delivery Translational Res. 2024;14(2):474\u201390.","journal-title":"Drug Delivery Translational Res"},{"issue":"1","key":"1700_CR89","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s43094-019-0015-8","volume":"6","author":"S Nangare","year":"2020","unstructured":"Nangare S, Dugam S. Smart invasome synthesis, characterizations, pharmaceutical applications, and pharmacokinetic perspective: a review. Future J Pharm Sci. 2020;6(1):1\u201321.","journal-title":"Future J Pharm Sci"},{"issue":"4","key":"1700_CR90","doi-asserted-by":"publisher","first-page":"571","DOI":"10.5530\/ijper.51.4.86","volume":"51","author":"AB Nair","year":"2017","unstructured":"Nair AB, et al. Poly (lactic acid-co-glycolic acid) Nanospheres improved the oral delivery of candesartan cilexetil. Indian J Pharm Educ Res. 2017;51(4):571\u20139.","journal-title":"Indian J Pharm Educ Res"},{"issue":"1","key":"1700_CR91","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1080\/10717544.2020.1760961","volume":"27","author":"R Verma","year":"2020","unstructured":"Verma R, Kaushik D. Design and optimization of candesartan loaded self-nanoemulsifying drug delivery system for improving its dissolution rate and pharmacodynamic potential. Drug Delivery. 2020;27(1):756\u201371.","journal-title":"Drug Delivery"},{"key":"1700_CR92","doi-asserted-by":"crossref","unstructured":"Venkatesan K et al. Development and optimization of Candesartan Cilexetil loaded solid lipid nanoparticles. Int J Pharm Invest, 2023. 13(4).","DOI":"10.5530\/ijpi.13.4.093"},{"key":"1700_CR93","doi-asserted-by":"crossref","unstructured":"\u00d6zt\u00fcrk A, Ayg\u00fcl A. Design of cefaclor monohydrate containing nanoparticles with extended antibacterial effect by nano-spray dryer: a nanoenglobing study. J Res Pharm, 2020. 24(1).","DOI":"10.35333\/jrp.2020.115"},{"issue":"5","key":"1700_CR94","first-page":"085","volume":"3","author":"MA Hossain","year":"2013","unstructured":"Hossain MA, Alam S, Paul P. Development and evaluation of sustained release matrix tablets of indapamide using Methocel K15M CR. J Appl Pharm Sci. 2013;3(5):085\u201390.","journal-title":"J Appl Pharm Sci"},{"issue":"3","key":"1700_CR95","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1161\/CIRCRESAHA.116.308441","volume":"120","author":"C Banerjee","year":"2017","unstructured":"Banerjee C, Chimowitz MI. Stroke caused by atherosclerosis of the major intracranial arteries. Circul Res. 2017;120(3):502\u201313.","journal-title":"Circul Res"},{"issue":"6","key":"1700_CR96","first-page":"52","volume":"17","author":"A Alloubani","year":"2021","unstructured":"Alloubani A, Nimer R, Samara R. Relationship between hyperlipidemia, cardiovascular disease and stroke: a systematic review. Curr Cardiol Rev. 2021;17(6):52\u201366.","journal-title":"Curr Cardiol Rev"},{"key":"1700_CR97","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1476-511X-10-23","volume":"10","author":"G Ji","year":"2011","unstructured":"Ji G, et al. Comparison of dietary control and atorvastatin on high fat diet induced hepatic steatosis and hyperlipidemia in rats. Lipids Health Dis. 2011;10:1\u201310.","journal-title":"Lipids Health Dis"},{"issue":"4","key":"1700_CR98","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1039\/C7FO00089H","volume":"8","author":"Z Zhu","year":"2017","unstructured":"Zhu Z, et al. Hypolipidemic effect of Youcha in hyperlipidemia rats induced by high-fat diet. Food Funct. 2017;8(4):1680\u20137.","journal-title":"Food Funct"},{"issue":"12","key":"1700_CR99","doi-asserted-by":"publisher","first-page":"3251","DOI":"10.1161\/STROKEAHA.107.485045","volume":"38","author":"M Shimamura","year":"2007","unstructured":"Shimamura M, et al. Delayed postischemic treatment with fluvastatin improved cognitive impairment after stroke in rats. Stroke. 2007;38(12):3251\u20138.","journal-title":"Stroke"},{"issue":"3","key":"1700_CR100","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3390\/scipharm85030029","volume":"85","author":"M Porwal","year":"2017","unstructured":"Porwal M, Khan NA, Maheshwari KK. Evaluation of acute and subacute oral toxicity induced by ethanolic extract of Marsdenia tenacissima leaves in experimental rats. Sci Pharm. 2017;85(3):29.","journal-title":"Sci Pharm"}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-024-01700-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13346-024-01700-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-024-01700-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T01:47:51Z","timestamp":1743904071000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13346-024-01700-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,11]]},"references-count":100,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["1700"],"URL":"https:\/\/doi.org\/10.1007\/s13346-024-01700-z","relation":{},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,11]]},"assertion":[{"value":"13 August 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Beni-Suef University\u2019s ethics commission in Egypt approved the study (BSU-IACUC: 022\u2013414).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors did not conduct any studies involving human.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors assert that there are no conflicts of interest to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}